Using the same sequence identity and coverage thresholds established above, we found that 1,863 out of 52,799 unlabeled BCR sequences from COVID-19 patients clustered with validated anti-SARS-CoV-2 antibodies from CovAbDab, resulting in 602 clusters. The gene discussed is BCR; the disease is COVID-19.